<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25885543</article-id><article-id pub-id-type="pmc">4351929</article-id><article-id pub-id-type="publisher-id">568</article-id><article-id pub-id-type="doi">10.1186/s13063-015-0568-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese medicine-defined constitutional types of healthy Chinese subjects: study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Sun</surname><given-names>Yue-li</given-names></name><address><email>edisonlike2008@gmail.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Hou</surname><given-names>Ting</given-names></name><address><email>houting90@126.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Liu</surname><given-names>Shu-fen</given-names></name><address><email>xiaoliufenfen@163.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Zhong-liang</given-names></name><address><email>307779122@qq.com</email></address><xref ref-type="aff" rid="Aff4"/></contrib><contrib contrib-type="author"><name><surname>Zhang</surname><given-names>Ning</given-names></name><address><email>ningzh18@126.com</email></address><xref ref-type="aff" rid="Aff3"/></contrib><contrib contrib-type="author"><name><surname>Yao</surname><given-names>Min</given-names></name><address><email>yaomin19871223@126.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Long</given-names></name><address><email>784472094@qq.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Qi</given-names></name><address><email>jzyjs200032@126.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Cui</surname><given-names>Xue-jun</given-names></name><address><email>13917715524@139.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Wang</surname><given-names>Yong-jun</given-names></name><address><email>yjwang8888@126.com</email></address><xref ref-type="aff" rid="Aff1"/><xref ref-type="aff" rid="Aff2"/></contrib><aff id="Aff1"><label/>Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725, South Wanping Road, Shanghai, 200032 P.R. China </aff><aff id="Aff2"><label/>Spine Institute, Shanghai University of Traditional Chinese Medicine, No. 725, South Wanping Road, Shanghai, 200032 P.R. China </aff><aff id="Aff3"><label/>College of Traditional Chinese Herbal Medicine, Shanghai University of Traditional Chinese Medicine, No. 1200 Cailun Road, Shanghai, 201203 P.R. China </aff><aff id="Aff4"><label/>Zhe Jiang Biosia Pharmaceutical Co., Ltd, No.1938 Xinqun Road, Pinghu City, Zhejiang Province P.R. China </aff></contrib-group><pub-date pub-type="epub"><day>26</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>26</day><month>2</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>64</elocation-id><history><date date-type="received"><day>6</day><month>11</month><year>2014</year></date><date date-type="accepted"><day>16</day><month>1</month><year>2015</year></date></history><permissions><copyright-statement>&#x000a9; Sun et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>High incidences of neck pain morbidity are challenging in various situations for populations based on their demographic, physiological and pathological characteristics. Chinese proprietary herbal medicines, as Complementary and Alternative Medicine (CAM) products, are usually developed from well-established and long-standing recipes formulated as tablets or capsules. However, good quantification and strict standardization are still needed for implementation of individualized therapies. The Qishe pill was developed and has been used clinically since 2009. The Qishe pill&#x02019;s personalized medicine should be documented and administered to various patients according to the ancient <italic>TCM</italic> system, a classification of personalized constitution types, established to determine predisposition and prognosis to diseases as well as therapy and life-style administration. Therefore, we describe the population pharmacokinetic profile of the Qishe pill and compare its metabolic rate in the three major constitution types (<italic>Qi-</italic>Deficiency, <italic>Yin</italic>-Deficiency and <italic>Blood-</italic>Stasis) to address major challenges to individualized standardized TCM.</p></sec><sec><title>Methods/Design</title><p>Healthy subjects (N = 108) selected based on constitutional types will be assessed, and standardized pharmacokinetic protocol will be used for assessing demographic, physiological, and pathological data. Laboratory biomarkers will be evaluated and blood samples collected for pharmacokinetics(PK) analysis and second-generation gene sequencing. In single-dose administrations, subjects in each constitutional type cohort (N = 36) will be randomly divided into three groups to receive different Qishe pill doses (3.75, 7.5 and 15 grams).</p><p>Multiomics, including next generation sequencing, metabolomics, and proteomics, will complement the Qishe pill&#x02019;s multilevel assessment, with cytochrome P450 genes as targets. In a comparison with the general population, a systematic population pharmacokinetic (PopPK) model for the Qishe pill will be established and verified.</p></sec><sec><title>Trial registration</title><p>This study is registered at ClinicalTrials.gov, <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT02294448">NCT02294448</ext-link>.15 November 2014.</p></sec><sec><title>Electronic supplementary material</title><p>The online version of this article (doi:10.1186/s13063-015-0568-6) contains supplementary material, which is available to authorized users.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Personalized medicine</kwd><kwd>Individualized medicine</kwd><kwd>Traditional Chinese Medicine</kwd><kwd>Multiomics</kwd><kwd>Population pharmacokinetics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Neck pain is one of the most common symptoms of cervical spine disease. Many treatments are available to patients and considered standard in clinical practice. They include common conservative strategies such as medication, physical methods, manual treatments, and education of patients. However, current evidence for the management of neck pain reveals that conservative interventions, especially Chinese herbal medicine, have not been studied in enough detail to assess their efficacy or effectiveness adequately [<xref ref-type="bibr" rid="CR1">1</xref>]. Possible reasons for the failure of current clinical practice to effectively manage neck pain lie in two main domains: first, the most difficult challenge faced is clinical heterogeneity, which appears at many levels, such as in the sample group, type of herbal medicine used and outcomes measured [<xref ref-type="bibr" rid="CR2">2</xref>]; and second, although Chinese proprietary herbal medicines are usually based on well-established and long-standing recipes and formulated as tablets or capsules for commerce, convenience and/or palatability, good quantification and strict detailed standardization still need to be improved.</p><p>As individualized diagnostic and therapeutic strategies have become a trend in modern medicine, they might help improve the efficacy and safety, predicting individual outcome and assessing risk, which make individualized prevention and early intervention strategies conceivable and practicable. According to the ancient <italic>TCM</italic> system, a classification of individualized constitution types has been established to determine predisposition and prognosis to diseases as well as therapy and life-style administration [<xref ref-type="bibr" rid="CR3">3</xref>]. An official Classification and Determination of TCM Constitution [<xref ref-type="bibr" rid="CR4">4</xref>] was released by the State Administration of TCM and the constitution branch of the Chinese Medical Association in April, 2009. Meanwhile, a standardized scale called Constitution in Chinese Medicine Questionnaire (CCMQ) [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR7">7</xref>] was designed based on the above classification. However, its reliability and validity has not been verified with comprehensive, large sample size trials. In the clinic, it takes a lot of practice for <italic>TCM</italic> specialists to be really efficient at adopting the four <italic>TCM</italic> examinations (observation, listening and smelling, inquiring, feeling the pulse and palpation) to totally assess the participants and determine their constitutional types based on physical, mental, physiological, and pathological attributes, which are called <italic>Ti Zhi.</italic> There are nine kinds of broad constitutional types with a varying degree of predisposition to different diseases (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). Among these, the three most contrasting constitutional types, <italic>Qi-</italic>Deficiency, <italic>Yin</italic>-Deficiency and <italic>Blood-</italic>Stasis, are the most vulnerable to chronic musculoskeletal diseases [<xref ref-type="bibr" rid="CR3">3</xref>]. In the realm of modern predictive medicine, efforts are being directed toward capturing disease phenotypes with greater precision for successful identification of markers for prospective disease conditions.<table-wrap id="Tab1"><label>Table 1</label><caption><p>
<bold>General characteristics of the nine traditional Chinese medicine</bold>
<italic>(</italic>
<bold>TCM) constitutional types</bold> [<xref ref-type="bibr" rid="CR3">3</xref>,<xref ref-type="bibr" rid="CR13">13</xref>,<xref ref-type="bibr" rid="CR14">14</xref>]</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>General characteristics</bold>
</th><th>
<bold>Physical characteristics</bold>
</th><th>
<bold>Psychological characteristics</bold>
</th><th>
<bold>Sign of health</bold>
</th><th>
<bold>Sign of illness</bold>
</th></tr></thead><tbody><tr valign="top"><td>Gentleness</td><td rowspan="2">
<italic>Yin-Yang</italic> balanced</td><td rowspan="2">Full of vitality and well-proportioned</td><td rowspan="2">Mild character</td><td rowspan="2">Good cold and hot tolerance, sleep well, good appetite and no fatigue</td><td rowspan="2">Less disease</td></tr><tr valign="top"><td>Type A</td></tr><tr valign="top"><td>
<italic>Qi-</italic>deficiency<sup>*</sup>
</td><td rowspan="2">Insufficiency of primordial <italic>Qi</italic>
</td><td rowspan="2">Weakened muscle<sup>*</sup>
</td><td rowspan="2">No desire to speak</td><td rowspan="2">Short of breath, listless and low voice and easy to sweat and fatigue</td><td rowspan="2">Palpitations and influenza</td></tr><tr valign="top"><td>Type B</td></tr><tr valign="top"><td>
<italic>Yang</italic>-deficiency</td><td rowspan="2">More insufficiency of primordial <italic>Qi</italic>
</td><td rowspan="2">Slightly muscle atrophy</td><td rowspan="2">More quiet and introverted</td><td rowspan="2">Intolerance of cold, loose stool, clear abundant urine and easy to catch a cold</td><td rowspan="2">Diarrhea</td></tr><tr valign="top"><td>Type C</td></tr><tr valign="top"><td>
<italic>Yin</italic>-deficiency<sup>*</sup>
</td><td rowspan="2">
<italic>Yin</italic>-fluid deficiency</td><td rowspan="2">Slim body</td><td rowspan="2">Quick-tempered</td><td rowspan="2">Feverish palms and soles, dry mouth and throat, dry eyes, flushing cheek, and dry skin is usual</td><td rowspan="2">Fatigue syndrome, muscle fatigue<sup>*</sup> and insomnia</td></tr><tr valign="top"><td>Type D</td></tr><tr valign="top"><td>Phlegm-wetness</td><td rowspan="2">Body fluid stasis and phlegm-wetness aggregation</td><td rowspan="2">Obese body with accumulate fat around abdomen</td><td rowspan="2">Prudent</td><td rowspan="2">Feeling body heaviness, chest distress and excessive phlegm, sticky mouth, and sticky sweating in usual</td><td rowspan="2">Stroke and Diabetes</td></tr><tr valign="top"><td>Type E</td></tr><tr valign="top"><td>Wet-heat</td><td rowspan="2">Internal accumulation of damp-heat</td><td rowspan="2">Slim body</td><td rowspan="2">Tend to be irritable</td><td rowspan="2">likely to suffer from acne, thirsty, bad breath, bitter taste in the mouth in usual</td><td rowspan="2">Constipation, scabies and jaundice</td></tr><tr valign="top"><td>Type F</td></tr><tr valign="top"><td>Blood-stasis<sup>*</sup>
</td><td rowspan="2">Poor blood circulation</td><td rowspan="2">All body types</td><td rowspan="2">Tend to be annoying and forgetful</td><td rowspan="2">Frequent pain<sup>*</sup> and ecchymosis and gloomy complexion</td><td rowspan="2">Chronic pain<sup>*</sup>
</td></tr><tr valign="top"><td>Type G</td></tr><tr valign="top"><td>
<italic>Qi-</italic>depression</td><td rowspan="2">Depression and stagnation of <italic>Qi</italic>
</td><td rowspan="2">Slim body</td><td rowspan="2">Depressive, sensitive and suspicious</td><td rowspan="2">Frequently sigh, distention and pain in chest</td><td rowspan="2">hypochondria</td></tr><tr valign="top"><td>Type H</td></tr><tr valign="top"><td>Special diathesis</td><td rowspan="2">Special diathesis</td><td rowspan="2">All body types</td><td rowspan="2">All types</td><td rowspan="2">Hypersensitiveness</td><td rowspan="2">Asthma and urticaria</td></tr><tr valign="top"><td>Type I</td></tr></tbody></table><table-wrap-foot><p>*The three TCM constitutional types (Qi-deficiency, Yin-deficiency and Blood-stasis) have been selected in this trial.</p></table-wrap-foot></table-wrap></p><p>In the early 1990s, the YQHYTL formula was proposed for neck pain and subsequently underwent further investigation to establish the medicine&#x02019;s efficacy. Based on the YQHYTL formula, the Qishe pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China), which is composed of processed <italic>Radix Astragali</italic>, <italic>Muscone, Szechuan Lovage Rhizome</italic>, <italic>Radix Stephaniae Tetrandrae</italic>, <italic>Caulis Sinomenii</italic>, and <italic>Calculus Bovis Artifactus</italic> (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>), was developed and has been widely used in clinical settings since 2009 [<xref ref-type="bibr" rid="CR8">8</xref>-<xref ref-type="bibr" rid="CR11">11</xref>]. The Qishe pill is a thin 0.15 g film-coated pill with a slightly penetrating odor and a mildly bitter flavor. Production and processing of the Qishe pill are described as follows: (1) the volatile oil is extracted from <italic>Szechuan Lovage Rhizome</italic> on standby; (2) the remaining drug decoction from <italic>Szechuan Lovage Rhizome</italic> is mixed with <italic>Radix Astragali,</italic> which has been soaked for 30 min, and simmered in 10 volumes of water, twice, for 2 hours each time; (3) the decoction is then vacuum filtrated to a relative density of 1.24 to 1.26 (70&#x000b0;C), and ethanol is added to the concentrated decoction to bring to a 70% alcohol content; (4) after filtration and concentration (ethanol recovery), the remaining sample is vacuum dried and then crushed into a fine powder; (5) from this mixture, which contains 14 volumes of 70% ethanol, <italic>Radix Stephaniae Tetrandrae</italic> and <italic>Caulis Sinomenii</italic> are extracted with the circumfluent alcohol, three times for 2 hours, concentrated with recovery of ethanol, vacuum dried again, and crushed into a fine powder; (6) the volatile oil of <italic>Szechuan Lovage Rhizome</italic> is then mixed with four parts &#x003b2;-cyclodextrin and dried under vacuum; and (7) the porphyrized powder of the <italic>Calculus Bovis Artifactus</italic> and <italic>Muscone</italic> are mixed with the &#x003b2;-cyclodextrin and the other two fine powders mentioned above, pelleted and coated, to obtain the pills called the Qishe pill (drug name).<table-wrap id="Tab2"><label>Table 2</label><caption><p>
<bold>Standard formula (capsule ingredients)*</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Chinese Name</bold>
</th><th>
<bold>Pharmaceutical Name</bold>
</th><th>
<bold>Powered Herb, %</bold>
</th></tr></thead><tbody><tr valign="top"><td>Huang Qi</td><td>
<italic>Radix Astragali</italic>
</td><td>28% (13g)</td></tr><tr valign="top"><td>She Xiang</td><td>
<italic>Muscone</italic>
</td><td>0. (0.03g)</td></tr><tr valign="top"><td>Chuan Xiong</td><td>
<italic>Szechuan Lovage Rhizome</italic>
</td><td>26% (12g)</td></tr><tr valign="top"><td>Fang Ji</td><td>
<italic>Radix Stephaniae Tetrandrae</italic>
</td><td>19% (9g)</td></tr><tr valign="top"><td>Qing Feng Teng</td><td>
<italic>Caulis Sinomenii</italic>
</td><td>26% (12g)</td></tr><tr valign="top"><td>Niu Huang</td><td>
<italic>Calculus Bovis Artifactus</italic>
</td><td>0. (0.3g)</td></tr></tbody></table><table-wrap-foot><p>*Pharmaceutical terminology from Hsu [<xref ref-type="bibr" rid="CR12">12</xref>].</p></table-wrap-foot></table-wrap></p><p>With the high incidence of neck pain morbidity [<xref ref-type="bibr" rid="CR13">13</xref>-<xref ref-type="bibr" rid="CR16">16</xref>], and the wide variety of population properties (age, gender, weight, constitutional type, history of disease and life style, etc.) involved, providing an individual patient with optimal treatment at a given time is challenging. Therefore, personalized administration of the Qishe pill should be documented and practiced with multiple patients. Thus, a comprehensive research concerning the population pharmacokinetics (PopPK) of the Qishe pill in Chinese subjects should be conducted. In this study, we describe the population pharmacokinetic profile of the Qishe pill and compare its extent of metabolism in the three major constitution types (<italic>Qi-</italic>Deficiency, <italic>Yin</italic>-Deficiency and <italic>Blood</italic>-Stasis) to address major challenges of individualized and standardized Traditional Chinese Medicine into clinical practice, as a pilot trial.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods/Design</title><sec id="Sec3"><title>Study design</title><p>This single-center, three cohort, open-label, double-Latin-sequence, crossover study will be conducted in 108 healthy adult subjects (36 subjects in each cohort) who meet the inclusion and exclusion criteria. The experiments will be conducted in accordance with good clinical practice procedures, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki. This study was approved by the ethics committee of the institutional review board in Longhua Hospital, Shanghai University of TCM (2013-LCSY-064). After completing baseline description of the study to the enrolled subjects, written informed consent will be obtained from each of them.</p><p>The sample size was established according to GCP guidelines of SFDA, which recommend 8 to 12 subjects in a clinical pharmacokinetic trial. The study will take place at the phase I unit of Longhua Hospital, Shanghai University of TCM from Nov. 2014 to Dec 2016.</p></sec><sec id="Sec4"><title>Study population</title><sec id="Sec5"><title>Inclusion and exclusion criteria</title><p>We will recruit three main cohorts with confirmed <italic>TCM</italic> constitutional types: <italic>Qi-</italic>Deficiency (n = 36), <italic>Yin</italic>-Deficiency (n = 36) and <italic>Blood-</italic>Stasis (n = 36). All subjects will be 20 to 35 years old and with normal weight (18.5 kg/m<sup>2</sup> &#x02264;BMI &#x0003c;23.0 kg/m<sup>2</sup>). The detailed inclusion and exclusion criteria are presented in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>.<table-wrap id="Tab3"><label>Table 3</label><caption><p>
<bold>Inclusion and exclusion criteria</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th/><th>
<bold>Criteria</bold>
</th></tr></thead><tbody><tr valign="top"><td>Inclusion</td><td>- Aged 20 to 35</td></tr><tr valign="top"><td/><td>- 18.5 kg/m<sup>2</sup> &#x02264;body mass index (BMI) &#x0003c;23 kg/m<sup>2</sup>
</td></tr><tr valign="top"><td/><td>- Traditional Chinese medicine (<italic>TCM)-</italic>constitutionally typed as one of the three major types</td></tr><tr valign="top"><td>Exclusion</td><td>- History of impaired fasting glucose or diabetes mellitus (past history of diabetes or fasting blood glucose at screening &#x02265;100 mg/dl)</td></tr><tr valign="top"><td/><td>- History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction (AST or ALT at screening &#x02265;40 U/L)</td></tr><tr valign="top"><td/><td>- History of renal dysfunction (creatinine at screening &#x02265;1.2 mg/dl)</td></tr><tr valign="top"><td/><td>- History of heart disease (heart failure, angina pectoris, myocardial infarction, arrhythmia)</td></tr><tr valign="top"><td/><td>- History of malignant tumor</td></tr><tr valign="top"><td/><td>- Having digestive disorders that can interfere with normal absorption of standard diet (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.)</td></tr><tr valign="top"><td/><td>- Smoking during the recent 3 months</td></tr><tr valign="top"><td rowspan="2"/><td>- Alcohol consumption three or more times a week during the recent 3 months</td></tr><tr valign="top"><td>- Women who were pregnant, intended to become pregnant, or breast- feeding</td></tr><tr valign="top"><td/><td>- Medicated during the recent month for therapeutic or prophylactic purposes</td></tr><tr valign="top"><td/><td>- Participating in another clinical trial</td></tr></tbody></table></table-wrap></p><p>All subjects will be surveyed beforehand for their demographic characteristics and lifestyle patterns. The screening will also include blood tests and the Constitution in Chinese Medicine Questionnaire (CCMQ). After exclusion of noneligible participants, the remaining subjects will be assigned identification codes.</p></sec></sec><sec id="Sec6"><title>Determination of TCM constitution</title><p>According to Classification and Determination of TCM Constitution [<xref ref-type="bibr" rid="CR4">4</xref>] released by the State Administration of TCM and the constitution branch of the Chinese Medical Association, two TCM specialists will adopt four <italic>TCM</italic> examinations (observation, listening and smelling, inquiring, feeling the pulse and palpation) to totally assess the participants and determine their constitutional types based on physical, mental, physiological, and pathological attributes.</p><p>The <italic>TCM</italic> specialists involved are qualified traditional Chinese medical doctors licensed by the Chinese government, with 6 years of traditional Chinese medicine training, minimum 3 years of training in <italic>TCM</italic>, and 9 years of further clinical experience. The constitutional type will be confirmed only when both make concordant decisions. The Constitution in Chinese Medicine Questionnaire (CCMQ) [<xref ref-type="bibr" rid="CR5">5</xref>-<xref ref-type="bibr" rid="CR7">7</xref>] will be used to improve objectiveness in decision-making.</p></sec><sec id="Sec7"><title>Study procedures</title><sec id="Sec8"><title>Laboratory measurements and clinical assessment</title><p>A specific set of laboratory parameters will be measured for every subject on the day of recruitment. These parameters include blood count, electrolyte levels, renal and liver function parameters, blood lipid amounts. Furthermore, age, gender, history of smoking, blood pressure, weight (kg), and height (meters) will be obtained for all subjects. Standard operating procedures have been defined for each clinical examination, including the measurements of blood pressure, height and weight [<xref ref-type="bibr" rid="CR17">17</xref>].</p></sec></sec><sec id="Sec9"><title>Drug administration</title><p>Thirty-six healthy adult subjects in each cohort will be randomly divided into three groups to receive three different doses (low, 3.75 g; middle, 7.5 g; or high, 15 g). Subjects will be randomly assigned following simple randomization procedures (computerized random numbers) to each subgroup. Each dose of the Qishe pill (Shanghai Sundise Traditional Chinese Medicine Co., Ltd, China) with the same lot number will be administered orally with water (240 ml) after at least 10-hour fast. The low dose (3.75 mg) was calculated according to the applicable regulatory guidance [<xref ref-type="bibr" rid="CR18">18</xref>,<xref ref-type="bibr" rid="CR19">19</xref>], using the No Observable Adverse Effect Level (NOAEL) in the most sensitive species (500 mg/kg/day in Sprague&#x02013;Dawley rats).</p><p>Subjects will be admitted to the study unit the evening before drug administration. On the day of administration, single doses of the Qishe pill will be taken orally, 1h after a standardized meal. Regular standardized meals will be provided 4 h after drug administration. Water is allowed as desired, except for 1 hour before and 2 hours after drug administration. The subjects will remain within a supervised investigational unit for the subsequent 3-d period for pharmacokinetic study and toxicity monitoring, providing 3-day blood and urine samples. Vital signs and clinical laboratory tests were done before and at 24 h after dosing. Furthermore, they will be requested to return to the study unit 4 d after drug administration for a follow-up visit.</p></sec><sec id="Sec10"><title>Sample collection</title><p>For the PK analysis and second-generation gene sequencing, 5 ml blood samples will be collected into tubes containing ammonium heparinate and centrifuged immediately at 4000 g for 10 min to obtain plasma samples. These samples will be then transferred into polypropylene vials and kept at &#x02212;20&#x000b0;C until analysis. For the 7.5 and 15 g dose groups, samples will be collected at dosing (time 0), and 15, 30, 45, 60, 90, 120, 150, 180, 240, 360, 480, 600, 720, 1440, 2160 and 2880 min.</p><p>Furthermore, a comprehensive set of biomaterials including EDTA-plasma (6 ml), serum (5 ml) and urine (6 ml) will be collected and stored for future laboratory analyses.</p></sec><sec id="Sec11"><title>Safety assessments</title><p>Safety and tolerability will be assessed subjectively and objectively. Subjective tolerability will be assessed by questioning subjects about any adverse events (AE). Objective tolerability will be assessed at scheduled intervals by vital signs (body temperature, heart rate and blood pressure), electrocardiograms (ECGs), the examination of intravenous infusion sites, and identification of adverse events (AEs). AE information will be collected throughout the study, based on spontaneous volunteer reports, interviews, clinical examinations and laboratory tests (hematology, serum biochemistry, and urinalysis). The investigators will assess all clinical AEs according to the Medical Dictionary for Regular Activities criteria, in terms of intensity (mild, moderate, or severe), duration, outcome and relationship to the study drug. Those which are life threatening, or lead to death, hospitalization, disability, or medical intervention to prevent permanent impairment or damage, will be considered as serious adverse events (SAE). Each adverse event occurring to a subject has to be recorded in the case-report form.</p><p>All study procedures are illustrated in Figure&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Figure 1</label><caption><p>
<bold>Patient flowchart detailing the process, including screening, allocation, and analysis.</bold>
</p></caption><graphic xlink:href="13063_2015_568_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec12"><title>Instrumentation and conditions</title><p>The LC-MS/MS system consists of an ULTIMATE 3000 series UHPLC (Thermo Fisher Scientific, USA) coupled to a TSQ QUANTUM ACCESS MAX Mass Spectrometer (Thermo scientific, USA). Chromatographic separation will be performed on a Waters Acquity UPLC BEH C18 column [100 mm*2.1 mm (i.d.); 1.7&#x003bc;m] (Waters, USA). The standards and samples will be separated using a mobile phase consisting of 0.1% formic acid in water (solvent A) and methanol (solvent A). The gradient elution program will be: 0&#x02013;1 min, 20% A; 1&#x02013;8 min, 20-100% A; 8&#x02013;12 min, 100% A; and then back to 20% A to recondition the column for 4 min. The flow rate of the mobile phase will be 0.3 ml/min, with the column temperature maintained at 40&#x000b0;C. ESI ionization performed in the positive ion mode with a spray voltage of 3,000 V and negative mode with a spray voltage of 2500 V will be used. Sheath gas pressure and aux gas pressure will be set at 35 psi and 5 psi, respectively. A capillary temperature of 350&#x000b0;C will be used. Quantification will be performed in the multiple reaction monitoring (MRM) mode. The optimized parameters, such as collision energy (CE) and the tube lens for each compound, are summarized in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. Xcalibur (Ver. 2.1; Thermo scientific, USA) is used to control the UHPLC/TSQ Quantum system, and to acquire and process data.<table-wrap id="Tab4"><label>Table 4</label><caption><p>
<bold>Multiple reaction monitoring (MRM) transitions for quantification of the nine target compounds</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Compound abbreviations*</bold>
</th><th>
<bold>Monitoring Mode</bold>
</th><th>
<bold>Parent (m/z)</bold>
</th><th>
<bold>Product (m/z)</bold>
</th><th>
<bold>Tube lens (V)</bold>
</th><th>
<bold>Collision energy (eV)</bold>
</th><th>
<bold>Retention times (min)</bold>
</th></tr></thead><tbody><tr valign="top"><td>CCS</td><td>[M + H]+</td><td>285.16</td><td>270.30</td><td>99</td><td>23</td><td>6.43</td></tr><tr valign="top"><td>CCSG</td><td>[M + H]+</td><td>447.24</td><td>285.30</td><td>98</td><td>20</td><td>4.89</td></tr><tr valign="top"><td>FAN</td><td>[M + H]+</td><td>623.44</td><td>381.40</td><td>130</td><td>40</td><td>4.89</td></tr><tr valign="top"><td>PAL</td><td>[M + H]+</td><td>352.23</td><td>336.30</td><td>89</td><td>29</td><td>5.44</td></tr><tr valign="top"><td>5-O-M</td><td>[M + H]+</td><td>453.27</td><td>291.30</td><td>108</td><td>22</td><td>6.01</td></tr><tr valign="top"><td>ONO</td><td>[M + H]+</td><td>431.25</td><td>269.30</td><td>97</td><td>17</td><td>6.00</td></tr><tr valign="top"><td>FOR</td><td>[M + H]+</td><td>269.20</td><td>197.30</td><td>97</td><td>34</td><td>7.32</td></tr><tr valign="top"><td>AST-IV</td><td>[M + Na]+</td><td>807.53</td><td>627.40</td><td>221</td><td>49</td><td>8.69</td></tr><tr valign="top"><td>BER</td><td>[M + H]+</td><td>336.19</td><td>320.28</td><td>94</td><td>30</td><td>5.38</td></tr></tbody></table><table-wrap-foot><p>*The compound abbreviations and their associated terms:</p><p>AST-IV: astragaloside IV; BER: berberine; CCS: calycosin; CCSG: calycosin-7-O-&#x003b2;-D- glucoside; FAN: fangchinoline; FOR: formononetin; ONO: ononin; PAL: palmatine; 5-O-M: 5-O-methylvisammioside.</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Analytical assays</title><p>Plasma concentrations and urinary excretion rates of the Qishe pill will be determined for up to 48 h using high-performance liquid chromatography with fluorometric detection according to a method used previously [<xref ref-type="bibr" rid="CR20">20</xref>].</p><p>For sample preparation, plasma samples (100 ml) will be mixed with 100 ml of internal standard (diphenhydramine, purchased from the National Institutes for Food and Drug Control, Beijing, China) working solution. The samples will be extracted with 11:1 methanol&#x02013;water (600 ml) by vortex-mixing for 1 min at high speed and centrifugation at 12,000xg for 10 min; 20 ml supernatant will be injected in the LC/MS/MS system for analysis.</p></sec><sec id="Sec14"><title>Pharmacokinetic parameters</title><p>The pharmacokinetic parameters of the Qishe pill will be estimated using noncompartmental methods. The actual blood sampling time will be used, and the maximum plasma concentration (<italic>C</italic><sub>max</sub>) and time to maximum concentration (<italic>T</italic><sub>max</sub>) will be recorded. The area under the plasma concentration-time curve (<italic>AUC</italic>) will be calculated using the linear trapezoidal rule. The elimination rate constant (<italic>k</italic><sub>e</sub> ) will be estimated from the least-squares regression slope of the terminal plasma concentration. The <italic>AUC</italic> from 0 to infinity (<italic>AUC</italic><sub>0&#x02212;&#x0221e;</sub>) will be calculated by (<italic>AUC</italic><sub>0&#x02192;t</sub> + <italic>C</italic><sub>t</sub> /<italic>k</italic><sub>e</sub> ) (<italic>C</italic><sub>t</sub> is the last plasma concentration measured). The elimination half-life (t<sub>1/2</sub>) will be calculated as ln 2/<italic>k</italic><sub>e</sub>. The distribution volume (DF) will be calculated by Dose/<italic>AUC</italic>/<italic>k</italic><sub>e</sub>.</p></sec><sec id="Sec15"><title>Deep phenotyping with genomics and functional genomics approaches</title><p>Within pharmacokinetics of the Qishe pill, standardized workflows for the omics characterization of biosamples will be developed. Currently, genomic variants will be analyzed for 144 subjects with the aid of the Human- CoreExome + v1.1-Psych Array. For a subset of 144 subjects, whole blood expression data will be generated using Illumina&#x02019;s HT-12 bead chips. The findings will be complemented with proteomic and metabolomic data using established workflows. Cytochrome P450 genes, such as CYP1A1, CYP1A2, CYP2D6, CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5, among other, will be the targets.</p><p>Metabolomics provide comprehensive snapshots of the metabolome of body fluids such as plasma or urine. High-throughput metabolomic analyses mainly based on 1H nuclear magnetic resonance (NMR) spectroscopy, a nondestructive analysis with minimal preparation requirements, will be performed. NMR spectroscopy provides robust and reproducible measurements. Mass spectrometry (MS) with high analytical sensitivity will be used for additional detailed studies.</p><p>Integrated analyses of these data for associations with clinical and subclinical phenotypes will be performed using the bioinformatics groups of the <italic>TCM</italic> constitutional type classification.</p></sec><sec id="Sec16"><title>Medical informatics and data management</title><p>The PopPK analysis will be performed with NONMEM [<xref ref-type="bibr" rid="CR21">21</xref>-<xref ref-type="bibr" rid="CR23">23</xref>]. The plasma concentration-time profiles for all constituents and derivatives of the Qishe pill will be described by a base structural model using the subroutine ADVAN5 [<xref ref-type="bibr" rid="CR24">24</xref>]. The PK structural model will be parameterized in terms of apparent clearance and apparent distribution volume (CL/F and V/F), where F is the unknown oral bioavailability; the clearance and distribution volume are CL<sub>M</sub> and V<sub>M</sub>, respectively. A Bayesian approach conditioned on the population characteristics will be used to estimate specific individual parameters. First-order conditional estimation methods (FOCE) and first-order conditional estimation methods with interaction (FOCE-I) will be tested during model development. The unexplained random variability in individual values of the structural model parameters will be described in the interindividual variability (IIV) model.</p><p>For the final model, a backward elimination process will be employed to identify significant covariates. The covariates in the full model will be excluded one by one. The objective function value (OFV) will be compared with that of the full model. A covariate will be retained in the model when its elimination results in an increase in the OFV of 7.88 (chi-square, <italic>P</italic> &#x0003c;0.005, <italic>df</italic> = 1). We will select the model according to the reduction in the OFV value, goodness-of-fit plots, reduction in the IIV of structure model parameters, residual error, robust model parameter estimation, and model stability. The architecture and basic elements of the PopPK research is illustrated in Figure&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Figure 2</label><caption><p>
<bold>Architecture and basic elements of the population pharmacokinetic (PopPK) research based on medical informatics and data management.</bold>
</p></caption><graphic xlink:href="13063_2015_568_Fig2_HTML" id="MO2"/></fig></p></sec></sec><sec id="Sec17" sec-type="discussion"><title>Discussion</title><p>Cervical radiculopathy is a significant public health problem worldwide, accounting for 60 to 70% of all cervical spondylopathy cases; it is generally believed that most symptoms can be cured or relieved by nonsurgical treatments [<xref ref-type="bibr" rid="CR25">25</xref>].</p><p>Previous evidence-based trials have reported that analgesics and nerve-nutrition medicines have considerable effects on neck pain. Even though analgesics, such as aspirin, seem to be relatively safe, gastrointestinal reactions are often reported after their use [<xref ref-type="bibr" rid="CR26">26</xref>]. Mecobalamin, a neuropathy drug, which relieves neck pain by stimulating the inhibition of nerve degeneration and improving the excitability of nerve fibers [<xref ref-type="bibr" rid="CR27">27</xref>], seems to be ineffective when degeneration occurs.</p><p>The Qishe pill provides specific benefits for &#x0201c;Qi and Blood&#x0201d;, terms in <italic>TCM</italic>, meaning that it can profit and activate blood circulation. We have previously shown that the Qishe pill reversibly inhibits the NF-&#x003ba;B pathway, which might be an underlying mechanism behind its anti-inflammatory potential in disc degeneration <italic>in vivo</italic> [<xref ref-type="bibr" rid="CR28">28</xref>]. Extensive investigations have confirmed that the Qishe pill has several therapeutic features, inhibiting platelet surface activity and platelet aggregation [<xref ref-type="bibr" rid="CR29">29</xref>], reducing the synthesis and release of local PGE [<xref ref-type="bibr" rid="CR30">30</xref>], decreasing malondialdehyde content in inflammatory exudates [<xref ref-type="bibr" rid="CR31">31</xref>], and inhibiting the IL-1beta-induced phosphorylation of extracellular signal-regulated kinases 1/2 and c-Jun N-terminal kinase [<xref ref-type="bibr" rid="CR32">32</xref>]<sub>.</sub> These effects include predictable pharmacokinetics (PK) and pharmacodynamics (PD) behaviors; in addition, the Qishe pill suppresses acute inflammatory reactions and pain events with fewer gastrointestinal discomfort and rash. A simple and sensitive method using ultra-high-performance liquid chromatography&#x02013;tandem mass spectrometry (UHPLC&#x02013;MS/MS) on a reverse-phase C18 column was developed for the simultaneous determination of the 19 major components of the Qishe pill [<xref ref-type="bibr" rid="CR20">20</xref>]. This method was successfully validated for the quantification of the 19 components in the Qishe pill products, and constitutes a new standard in quality assessment of TCM prescriptions containing multiple bioactive components (see Additional file <xref rid="MOESM1" ref-type="media">1</xref>). Over the last few years, several interactions between the Qishe pill ingredients and the pharmacokinetics of flavonoids (calycosin and calycosin-7-o--d-glycoside), alkaloids (tetrandrine, fangchinoline, magnoflorine and berberine hydrochloride), ferulic acid and glycosides (astragaloside IV, astragalussaponin I and III) have been reported [<xref ref-type="bibr" rid="CR20">20</xref>,<xref ref-type="bibr" rid="CR33">33</xref>-<xref ref-type="bibr" rid="CR37">37</xref>]. Furthermore, HPLC-TQ/MS was employed to detect the component contents in the Qishe pill, whose partial pharmacokinetic parameters are shown in Table&#x000a0;<xref rid="Tab5" ref-type="table">5</xref>.<table-wrap id="Tab5"><label>Table 5</label><caption><p>
<bold>Pharmacokinetic parameter after oral administration of Qishe pill at a dose of 6.33 g&#x02022;kg-1 to SD rats (mean &#x000b1; SD, n = 6)</bold>
</p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th>
<bold>Parameters</bold>
</th><th>
<bold><italic>SEA</italic></bold>
</th><th>
<bold><italic>SEI</italic></bold>
</th><th>
<bold><italic>FOR</italic></bold>
</th><th>
<bold><italic>ONO</italic></bold>
</th><th>
<bold><italic>5-O-M</italic></bold>
</th><th>
<bold><italic>AST-IV</italic></bold>
</th></tr></thead><tbody><tr valign="top"><td>
<bold><italic>t</italic></bold>
<sub>1/2</sub>
<bold>(h)</bold>
</td><td>22.72&#x02009;&#x000b1;&#x02009;11.49</td><td>12.35&#x02009;&#x000b1;&#x02009;10.3</td><td>51.24&#x02009;&#x000b1;&#x02009;44.19</td><td>7.04&#x02009;&#x000b1;&#x02009;3.7</td><td>42.79&#x02009;&#x000b1;&#x02009;16.29</td><td>11.41&#x02009;&#x000b1;&#x02009;12.51</td></tr><tr valign="top"><td>
<bold><italic>C</italic></bold>
<sub>max</sub>
<bold>(ng/ml)</bold>
</td><td>53.71&#x02009;&#x000b1;&#x02009;16.14</td><td>136.51&#x02009;&#x000b1;&#x02009;45.24</td><td>9.39&#x02009;&#x000b1;&#x02009;4.32</td><td>2.45&#x02009;&#x000b1;&#x02009;1.51</td><td>0.14&#x02009;&#x000b1;&#x02009;0.07</td><td>13.3&#x02009;&#x000b1;&#x02009;5.42</td></tr><tr valign="top"><td>
<bold><italic>T</italic></bold>
<sub>max</sub>
<bold>(h)</bold>
</td><td>0.22&#x02009;&#x000b1;&#x02009;0.07</td><td>0.31&#x02009;&#x000b1;&#x02009;0.16</td><td>0.22&#x02009;&#x000b1;&#x02009;0.07</td><td>0.25&#x02009;&#x000b1;&#x02009;0.00</td><td>0.25&#x02009;&#x000b1;&#x02009;0.00</td><td>2.00&#x02009;&#x000b1;&#x02009;2.25</td></tr><tr valign="top"><td>
<bold><italic>AUC</italic></bold>
<sub>last</sub>(h*ng/ml)</td><td>606.87&#x02009;&#x000b1;&#x02009;161.89</td><td>851.3&#x02009;&#x000b1;&#x02009;251.31</td><td>38.1&#x02009;&#x000b1;&#x02009;8.04</td><td>4.17&#x02009;&#x000b1;&#x02009;1.53</td><td>1.13&#x02009;&#x000b1;&#x02009;0.10</td><td>107.74&#x02009;&#x000b1;&#x02009;65.65</td></tr><tr valign="top"><td>
<bold><italic>AUC</italic></bold>
<sub>tot</sub>(h*ng/ml)</td><td>826.3&#x02009;&#x000b1;&#x02009;229.51</td><td>900.76&#x02009;&#x000b1;&#x02009;236.67</td><td>71.57&#x02009;&#x000b1;&#x02009;26.49</td><td>4.89&#x02009;&#x000b1;&#x02009;1.65</td><td>2.31&#x02009;&#x000b1;&#x02009;0.41</td><td>129.75&#x02009;&#x000b1;&#x02009;61.01</td></tr><tr valign="top"><td>
<bold><italic>MRT</italic></bold>
<bold>(h)</bold>
</td><td>36.54&#x02009;&#x000b1;&#x02009;15.27</td><td>16.58&#x02009;&#x000b1;&#x02009;6.89</td><td>70.4&#x02009;&#x000b1;&#x02009;60.63</td><td>9.55&#x02009;&#x000b1;&#x02009;4.04</td><td>65.96&#x02009;&#x000b1;&#x02009;20.60</td><td>17.9&#x02009;&#x000b1;&#x02009;17.38</td></tr><tr valign="top"><td>
<bold><italic>CL</italic></bold>
<bold>(L/h/kg)</bold>
</td><td>0.05&#x02009;&#x000b1;&#x02009;0.01</td><td>0.02&#x02009;&#x000b1;&#x02009;0.01</td><td>0.02&#x02009;&#x000b1;&#x02009;0.00</td><td>0.12&#x02009;&#x000b1;&#x02009;0.05</td><td>0.16&#x02009;&#x000b1;&#x02009;0.03</td><td>0.06&#x02009;&#x000b1;&#x02009;0.07</td></tr><tr valign="top"><td>
<bold><italic>V</italic></bold>
<bold>z (L/kg)</bold>
</td><td>1.41&#x02009;&#x000b1;&#x02009;0.67</td><td>0.41&#x02009;&#x000b1;&#x02009;0.33</td><td>0.98&#x02009;&#x000b1;&#x02009;0.43</td><td>1.12&#x02009;&#x000b1;&#x02009;0.83</td><td>9.38&#x02009;&#x000b1;&#x02009;2.09</td><td>0.83&#x02009;&#x000b1;&#x02009;0.94</td></tr></tbody></table></table-wrap></p><p>In the pre-trial of limited size (n = 6), accordingly, a UPLC-TQ/MS method for simultaneous determination of plasma concentrations of 15 bio-active Qishe pill constituents was developed and validated. The results showed that the method was selective, sensitive, precise, accurate, and reliable for comparative quantification of ferulic acid, calycosin, calycosin glycosides,calycosin-7-O-&#x003b2;-glucoside, ononin, formononetin, astragaloside, tetrandrine, fangchinoline base, berberine, tetrahydroberberine, tetrahydropalmatine, sinomenine and magnolia base, in human plasma samples. The mean plasma concentration&#x02013;time profiles of the major bio-active components determined after oral administration of Qishe pills are illustrated in Figure&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>.<fig id="Fig3"><label>Figure 3</label><caption><p>
<bold>Mean plasma concentration-time curves of seven components after oral administration of the Qishe pill at medium and high dosages (n = 4).</bold>
</p></caption><graphic xlink:href="13063_2015_568_Fig3_HTML" id="MO3"/></fig></p><p>According to the results of the pilot trial, further research should be conducted with modified protocol in dosage setting, requirements of sample collection (diet specifications, blood-collection time window) and sample processing.</p><sec id="Sec18"><title>Highlights</title><p>Diagnosis and treatment based on an overall analysis of the illness and patient&#x02019;s condition is the essence of the <italic>TCM</italic> theory. Rational medication is dependent upon a basic understanding of the way patients handle drugs (pharmacokinetics) and their response to specific drug effects (pharmacodynamics). Moreover, <italic>TCM</italic> constitutional types in traditional Chinese recipes could significantly influence the plasma concentration-time and their pharmacokinetic parameters after oral administration [<xref ref-type="bibr" rid="CR38">38</xref>,<xref ref-type="bibr" rid="CR39">39</xref>]. As data collection and OMICS analyses in PopPK of the Qishe pill will be processed simultaneously, research is focusing on the analyses of PK, OMICS and laboratory data to generate new hypotheses for translational research such as individualized dose, individualized scope of <italic>TCM</italic> and trial simulation.</p><p>The present study will establish three cohorts to detect potential differences in pharmacokinetic characteristics of the Qishe pill constituents in the three different <italic>TCM</italic> constitutional types, to assess whether the rate and extent of drug metabolism will be altered in <italic>Qi-</italic>deficiency or <italic>Blood</italic>-stasis constitutional types. If the differences in the Qishe Pill pharmacokinetics among the three major constitutional groups were known, personalized medication strategies for people with the three major constitutional types could be provided for the application of TCM.</p></sec></sec><sec id="Sec19"><title>Trial status</title><p>Participant recruitment and prescreening began in December 2014. Blank control serum samples have been collected for standardization of the general methodology and normal conditions.</p></sec></body><back><app-group><app id="App1"><sec id="Sec20"><title>Additional file</title><p><media position="anchor" xlink:href="13063_2015_568_MOESM1_ESM.jpeg" id="MOESM1"><label>Additional file 1:</label><caption><p>
<bold>Typical chromatograms of ultrahigh-performance LC and tandem mass spectrometry (UHPLC-MS/MS) for (a) the mixed standard substance and (b) a sample [</bold>
<xref ref-type="bibr" rid="CR32">32</xref>
<bold>].</bold>
</p></caption></media></p></sec></app></app-group><glossary><title>Abbreviations</title><def-list><def-list><def-item><term>AST-III</term><def><p>Astragaloside III</p></def></def-item><def-item><term>AST-IV</term><def><p>Astragaloside IV</p></def></def-item><def-item><term><italic>AUC</italic></term><def><p>area under the plasma concentration&#x02013;time curve</p></def></def-item><def-item><term>BER</term><def><p>Berberine</p></def></def-item><def-item><term>CA</term><def><p>Cholic acid</p></def></def-item><def-item><term>CCS</term><def><p>Calycosin</p></def></def-item><def-item><term>CCSG</term><def><p>Calycosin-7-O-&#x003b2;-D- glucoside</p></def></def-item><def-item><term>CE</term><def><p>Collision energy</p></def></def-item><def-item><term><italic>C</italic><sub>max</sub></term><def><p>Maximum plasma concentration</p></def></def-item><def-item><term>DF</term><def><p>Distribution volume</p></def></def-item><def-item><term>CL/F</term><def><p>Apparent clearance</p></def></def-item><def-item><term>CL<sub>M</sub></term><def><p>Clearance</p></def></def-item><def-item><term>DAI</term><def><p>Daidzein</p></def></def-item><def-item><term>FAN</term><def><p>Fangchinoline</p></def></def-item><def-item><term>FOCE</term><def><p>First-order conditional estimation methods</p></def></def-item><def-item><term>FOCE-I</term><def><p>First-order conditional estimation methods with interaction</p></def></def-item><def-item><term>FOR</term><def><p>Formononetin</p></def></def-item><def-item><term>GA</term><def><p>Gallic acid</p></def></def-item><def-item><term><italic>k</italic><sub>e</sub></term><def><p>Elimination rate constant</p></def></def-item><def-item><term>MS</term><def><p>Mass spectrometry</p></def></def-item><def-item><term>MRM</term><def><p>Multiple reaction monitoring</p></def></def-item><def-item><term>NMR</term><def><p>Nuclear magnetic resonance</p></def></def-item><def-item><term>OFV</term><def><p>Objective function value</p></def></def-item><def-item><term>ONO</term><def><p>Ononin</p></def></def-item><def-item><term>PAL</term><def><p>Palmatine</p></def></def-item><def-item><term>PD</term><def><p>Pharmacodynamics</p></def></def-item><def-item><term>PK</term><def><p>Pharmacokinetics</p></def></def-item><def-item><term>PopPK</term><def><p>Population pharmacokinetic</p></def></def-item><def-item><term>SEA</term><def><p>Senkyunolide A</p></def></def-item><def-item><term>SEI</term><def><p>Senkyunolide I</p></def></def-item><def-item><term>SIN</term><def><p>Sinomenine</p></def></def-item><def-item><term>TCM</term><def><p>Traditional Chinese Medicine</p></def></def-item><def-item><term><italic>T</italic><sub>max</sub></term><def><p>Time to maximum concentration</p></def></def-item><def-item><term>UHPLC&#x02013;MS/MS</term><def><p>Ultra-high-performance liquid chromatography&#x02013;tandem mass spectrometry</p></def></def-item><def-item><term>V/F</term><def><p>Apparent distribution volume</p></def></def-item><def-item><term>V<sub>M</sub></term><def><p>Distribution volume</p></def></def-item><def-item><term>5-O-M</term><def><p>5-O-methylvisammioside</p></def></def-item></def-list></def-list></glossary><fn-group><fn><p>Yue-li Sun and Ting Hou contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>YLS participated in the study design, drafted the manuscript, and conducted the clinical procedure and sample collection. TH participated in the study design, revised the manuscript, and conducted the PK analysis and statistical modeling. SFL and ZLZ participated in statistical design and conducted the preliminary animal PK/PD analysis. MY and LY conducted the clinical procedure and sample collection. QS formulated the Qishe pill and provided academic advice in the Qishe pill administration. YJW, NZ and XJC gave administrative support for the study. YJW is the general supervisor for this research and participated in both the study design and critical revision of the manuscript. All authors read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>Yue-li Sun and Ting Hou are co-first authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The National TCM clinical research base was supported by State Administration of Traditional Chinese Medicine; Clinical Research Project of Traditional Chinese Medicine was supported by the State Administration of Traditional Chinese Medicine (201107004), &#x0201c;Three-year&#x0201d; project for promoting development of TCM in Shanghai (2014-2016) supported by Shanghai Municipal Commission of Health and Family Planning(ZY3-CCCX-3-2005); Selection and training project for excellent technician of Shanghai University of Traditional Chinese Medicine; &#x0201c;Shu Guang&#x0201d; project supported by Shanghai Municipal Education Commission; Shanghai Education Development Foundation(10GG20); Longhua Medical Team Project (LYTD-13); &#x0201c;Project Grant&#x0201d; supported by National Science Fund of China (81373666); &#x0201c;Innovation Team&#x0201d; development projects supported by Ministry of Education (IRT1270); &#x0201c;TCM Key projects&#x0201d; were supported by dept. of Science and Technology in Shanghai (14401970401).</p></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aker</surname><given-names>PD</given-names></name><name><surname>Gross</surname><given-names>AR</given-names></name><name><surname>Goldsmith</surname><given-names>CH</given-names></name><name><surname>Peloso</surname><given-names>P</given-names></name></person-group><article-title>Conservative management of mechanical neck pain: systematic overview and meta-analysis</article-title><source>BMJ</source><year>1996</year><volume>313</volume><issue>7068</issue><fpage>1291</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1136/bmj.313.7068.1291</pub-id><pub-id pub-id-type="pmid">8942688</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="other">Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical degenerative disc disease. Cochrane Database Syst Rev. 2010; (1), CD006556</mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="other">Wang Q. Classification of the nine basic <italic>TCM</italic> constitutional type and based expression and diagnosis. J Beijing University Tradit Chin Med. 2005(04); 1-8.</mixed-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>YB</given-names></name></person-group><article-title>Epidemiological investigation of constitutional types of Chinese medicine in general population: Base on 21,948 epidemiological investigation data of nine provinces in China</article-title><source>ZhongHuaZhong Yi Yao ZaZhi</source><year>2009</year><volume>24</volume><fpage>7</fpage><lpage>12</lpage></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Zhu</surname><given-names>YB</given-names></name><name><surname>Xue</surname><given-names>HS</given-names></name></person-group><article-title>Primary compiling of constitution in Chinese Medicine questionnaire</article-title><source>ZhongGuo Lin Chuang Kang Fu</source><year>2006</year><volume>10</volume><fpage>12</fpage><lpage>4</lpage></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YB</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Xue</surname><given-names>HS</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name></person-group><article-title>Preliminary assessment on performance of constitution in Chinese medicine questionnaire</article-title><source>ZhongGuo Lin Chuang Kang Fu</source><year>2006</year><volume>10</volume><fpage>15</fpage><lpage>7</lpage></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>YB</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name></person-group><article-title>Evaluation on reliability and validity of the constitution in Chinese medicine questionnaire (CCMQ)</article-title><source>ZhongGuo Xing Wei Yi XueKeXue</source><year>2007</year><volume>16</volume><fpage>651</fpage><lpage>4</lpage></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mei</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name></person-group><article-title>Purification process research of major compound in Qishe Pill as Astragalus</article-title><source>Acta Chin Med Pharmacol</source><year>2006</year><volume>34</volume><fpage>14</fpage><lpage>6</lpage></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name></person-group><article-title>Quality standard research of Qishe Pill</article-title><source>Lishizhen Med Mater Med Res</source><year>2008</year><volume>19</volume><fpage>977</fpage><lpage>9</lpage></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Zhang</surname><given-names>YQ</given-names></name><name><surname>Zhou</surname><given-names>CJ</given-names></name></person-group><article-title>Technology research of Qishe Pill, a new medicine for cervical spondylosis</article-title><source>Lishizhen Med Mater Med Res</source><year>2010</year><volume>21</volume><fpage>176</fpage><lpage>9</lpage></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>JR</given-names></name><name><surname>Wang</surname><given-names>HM</given-names></name><name><surname>Meng</surname><given-names>CX</given-names></name><name><surname>Tong</surname><given-names>PJ</given-names></name></person-group><article-title>Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical radiculopathy: a randomized controlled trial for Phase III</article-title><source>Chin J New Drugs Clin</source><year>2014</year><volume>7</volume><fpage>56</fpage><lpage>8</lpage></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>H-Y</given-names></name></person-group><source>1986 Oriental MateriaMedica</source><year>1986</year><publisher-loc>Long Beach, CA</publisher-loc><publisher-name>Oriental Healing Arts Institute</publisher-name></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maurer</surname><given-names>K</given-names></name></person-group><article-title>U.S. Department of Health, Education, and Welfare. Basic data on arthritis knee, hip and sacroiliac joints in adults ages 25&#x02013;74 years: United States, 1971&#x02013;1975</article-title><source>Health Stat</source><year>1979</year><volume>11</volume><fpage>1</fpage><lpage>31</lpage></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>M&#x000e4;kel&#x000e4;</surname><given-names>M</given-names></name><name><surname>Heli&#x000f6;vaara</surname><given-names>M</given-names></name><name><surname>Sievers</surname><given-names>K</given-names></name><name><surname>Impivaara</surname><given-names>O</given-names></name><name><surname>Knekt</surname><given-names>P</given-names></name><name><surname>Aromaa</surname><given-names>A</given-names></name></person-group><article-title>Prevalence, determinants, and consequences of chronic neck pain in Finland</article-title><source>Am J Epidemiol</source><year>1991</year><volume>134</volume><fpage>1356</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">1755449</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bovim</surname><given-names>G</given-names></name><name><surname>Schrader</surname><given-names>H</given-names></name><name><surname>Sand</surname><given-names>T</given-names></name></person-group><article-title>Neck pain in the general population</article-title><source>Spine (Phila Pa 1976)</source><year>1994</year><volume>19</volume><fpage>1307</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1097/00007632-199406000-00001</pub-id><pub-id pub-id-type="pmid">8066508</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van der Donk</surname><given-names>J</given-names></name><name><surname>Schouten</surname><given-names>JS</given-names></name><name><surname>Passchier</surname><given-names>J</given-names></name><name><surname>van Romunde</surname><given-names>LK</given-names></name><name><surname>Valkenburg</surname><given-names>HA</given-names></name></person-group><article-title>The associations of neck pain with radiological abnormalities of the cervical spine and personality traits in a general population</article-title><source>J Rheumatol</source><year>1991</year><volume>18</volume><fpage>1884</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">1795327</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>V</given-names></name></person-group><article-title>WHO reassesses appropriate body-mass index for Asian populations</article-title><source>Lancet</source><year>2002</year><volume>360</volume><fpage>235</fpage><pub-id pub-id-type="doi">10.1016/S0140-6736(02)09512-0</pub-id><pub-id pub-id-type="pmid">12133671</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="other">FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers; July, 2005, <ext-link ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf">http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf</ext-link>.</mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">EMEA. Strategies to identify and mitigate risks for first-in-human clinical trialswith investigational medicinal products; Sept. 2009, <ext-link ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf</ext-link>.</mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="other">Zhang ZL, Li Q, Li QF, Du SM, Zhou YQ, Lv CM, et al. Simultaneous determination of nineteen major components in Qishe Pill by ultra-high-performance liquid chromatography&#x02013;tandem mass spectrometry. Acta Pharmaceutica Sinica B (2014); <ext-link ext-link-type="uri" xlink:href="http://www.dx.doi.org/10.1016/j.apsb.2014.05.003">http://www.dx.doi.org/10.1016/j.apsb.2014.05.003</ext-link></mixed-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheiner</surname><given-names>LB</given-names></name><name><surname>Beal</surname><given-names>SL</given-names></name></person-group><article-title>Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data</article-title><source>J Pharmacokinet Biopharm</source><year>1980</year><volume>8</volume><fpage>553</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1007/BF01060053</pub-id><pub-id pub-id-type="pmid">7229908</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheiner</surname><given-names>BL</given-names></name><name><surname>Beal</surname><given-names>SL</given-names></name></person-group><article-title>Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experi- mental pharmacokinetic data</article-title><source>J Pharmacokinet Biopharm</source><year>1981</year><volume>9</volume><fpage>635</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1007/BF01061030</pub-id><pub-id pub-id-type="pmid">7334463</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheiner</surname><given-names>LB</given-names></name><name><surname>Beal</surname><given-names>SL</given-names></name></person-group><article-title>Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data</article-title><source>J Pharmacokinet Biopharm</source><year>1983</year><volume>11</volume><fpage>303</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1007/BF01061870</pub-id><pub-id pub-id-type="pmid">6644555</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Pollock</surname><given-names>BG</given-names></name><name><surname>Coley</surname><given-names>K</given-names></name><name><surname>Marder</surname><given-names>S</given-names></name><name><surname>Miller</surname><given-names>D</given-names></name><name><surname>Kirshner</surname><given-names>M</given-names></name><etal/></person-group><article-title>Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study</article-title><source>Br J Clin Pharmacol</source><year>2008</year><volume>66</volume><fpage>629</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">18771484</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qingmao</surname><given-names>Y</given-names></name></person-group><article-title>An 80-cases clinical observation of two conservative therapy of traditional Chinese and western medicine to cervical spondylotic radiculopathy</article-title><source>Chinese Foreign Health Abs</source><year>2010</year><volume>18</volume><fpage>223</fpage><lpage>5</lpage></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bin-Chia Wu</surname><given-names>D</given-names></name><name><surname>Tsai</surname><given-names>YW</given-names></name><name><surname>Wen</surname><given-names>YW</given-names></name></person-group><article-title>Bayesian cost-effectiveness analysis for censored data-an application to antiplatelet therapy</article-title><source>J Med Econ</source><year>2012</year><volume>15</volume><fpage>434</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.3111/13696998.2011.653510</pub-id><pub-id pub-id-type="pmid">22196038</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Okada</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>H</given-names></name><name><surname>Temporin</surname><given-names>K</given-names></name><name><surname>Okamoto</surname><given-names>M</given-names></name><name><surname>Kuroda</surname><given-names>Y</given-names></name><name><surname>Moritomo</surname><given-names>H</given-names></name><etal/></person-group><article-title>Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle and promotes nerve regeneration in a rat sciatic nerve injury model</article-title><source>Exp Neurol</source><year>2010</year><volume>222</volume><fpage>191</fpage><lpage>203</lpage><pub-id pub-id-type="doi">10.1016/j.expneurol.2009.12.017</pub-id><pub-id pub-id-type="pmid">20045411</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>WJ</given-names></name><name><surname>Hufnagl</surname><given-names>P</given-names></name><name><surname>Binder</surname><given-names>BR</given-names></name></person-group><article-title>Anti-inflammatory activity of astragaloside IV is mediated by inhibition of NF-qB activation and adhesion molecule expression</article-title><source>Thromb Haemost</source><year>2003</year><volume>90</volume><fpage>904</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">14597987</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>SL</given-names></name><name><surname>Jiang</surname><given-names>GH</given-names></name></person-group><article-title>Security and pharmacilogical effects of Szechuan Lovage Rhizome extract</article-title><source>J Chengdu UnivTradit Chin Med</source><year>2009</year><volume>32</volume><fpage>63</fpage><lpage>5</lpage></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>XJ</given-names></name><name><surname>Qiu</surname><given-names>MF</given-names></name></person-group><article-title>Clinical research progress of the pharmacology of ovientvine</article-title><source>J China&#x02019;s Integrated Tradit Chin Western Med Surg</source><year>2005</year><volume>11</volume><fpage>363</fpage><lpage>4</lpage></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Yu</surname><given-names>QH</given-names></name></person-group><article-title>Anti-inflammatory effects of Calculus BovisArtifactus: apilot study</article-title><source>J Shengyang Pharm Univ</source><year>2000</year><volume>17</volume><fpage>431</fpage><lpage>3</lpage></element-citation></ref><ref id="CR32"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liang</surname><given-names>QQ</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name></person-group><article-title>Muscone protects vertebral end-plate degeneration by anti-inflammatory property</article-title><source>ClinOrthop Relat Res</source><year>2010</year><volume>468</volume><fpage>1600</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1007/s11999-009-1079-0</pub-id></element-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>SM</given-names></name><name><surname>Pan</surname><given-names>YF</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title>Simultaneous determination with HPLC internal standard method for nine kinds ingredients in Qishe Pill</article-title><source>Chin Tradit Pat Med</source><year>2012</year><volume>7</volume><fpage>1271</fpage><lpage>5</lpage></element-citation></ref><ref id="CR34"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Du</surname><given-names>SM</given-names></name><name><surname>Li</surname><given-names>QF</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title>Effects of Qishe Pill on cervical radiculopathy rat model with <italic>Qi-</italic>deficiency and <italic>Blood</italic>-stasis syndrome</article-title><source>Pharmacol Clin</source><year>2013</year><volume>4</volume><fpage>118</fpage><lpage>21</lpage></element-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>SM</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>QF</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Zhang</surname><given-names>N</given-names></name></person-group><article-title><italic>Invivo</italic> tissue distribution research of ingredients in Qishe Pill</article-title><source>Chin J Exp Formulas Chin Med</source><year>2013</year><volume>19</volume><fpage>171</fpage><lpage>6</lpage></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>SL</given-names></name><name><surname>Bian</surname><given-names>YY</given-names></name><name><surname>Guan</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>P</given-names></name></person-group><article-title>Simultaneous analysis of seven astragalosides in Radix Astragali and related preparations by liquid chromatography coupled with electrospray ionization time-of-flight mass spectrometry</article-title><source>J Sep Sci</source><year>2006</year><volume>29</volume><fpage>2012</fpage><lpage>22</lpage><pub-id pub-id-type="doi">10.1002/jssc.200500486</pub-id><pub-id pub-id-type="pmid">17017014</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>QT</given-names></name><name><surname>Qi</surname><given-names>LW</given-names></name><name><surname>Li</surname><given-names>P</given-names></name><name><surname>Yi</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Bi</surname><given-names>ZM</given-names></name></person-group><article-title>Determination of seventeen main flavonoids and saponins in the medicinal plant Huang-qi (Radix Astragali) by HPLC-DAD-ELSD</article-title><source>J Sep Sci</source><year>2007</year><volume>30</volume><fpage>1292</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/jssc.200600422</pub-id><pub-id pub-id-type="pmid">17623470</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>P</given-names></name><name><surname>Wen</surname><given-names>AD</given-names></name><name><surname>Wang</surname><given-names>LL</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name></person-group><article-title>Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its verification (I)</article-title><source>World J Gastroenterol</source><year>2000</year><volume>6</volume><fpage>384</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">11819604</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>ZF</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Qiao</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Jia</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis syn- drome rats</article-title><source>J Ethnopharmacol</source><year>2010</year><volume>129</volume><fpage>1</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1016/j.jep.2010.02.023</pub-id><pub-id pub-id-type="pmid">20206677</pub-id></element-citation></ref></ref-list></back></article>